Hengjun Chao
Overview
Explore the profile of Hengjun Chao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bharadwaj A, Kelly M, Kim D, Chao H
Blood
. 2009 Dec;
115(3):500-9.
PMID: 19965663
The nature of viral vectors is suggested to be a significant contributor to undesirable immune responses subsequent to gene transfer. Such viral vectors, recognized as danger signals by the host...
2.
Kelly M, Bharadwaj A, Tacke F, Chao H
Mol Ther
. 2009 Nov;
18(2):361-9.
PMID: 19935782
Regulatory T cells play a major role in induction and maintenance of immune tolerance and immunological homeostasis. A variety of strategies have been attempted to induce regulatory T cells for...
3.
Kelly M, Zhuo J, Bharadwaj A, Chao H
Mol Ther
. 2009 Feb;
17(5):857-63.
PMID: 19240690
Direct intramuscular injection (IM) of adeno-associated virus (AAV) has been proven a safe and potentially efficient procedure for gene therapy of many genetic diseases including hemophilia B. It is, however,...
4.
Chao H, Walsh C
Expert Rev Mol Med
. 2006 Jan;
8(1):1-8.
PMID: 16401355
The mainstay of gene transfer studies is the use of wild-type cDNAs to effect phenotypic correction of diseases. However, this strategy is not feasible for genetic diseases caused either by...
5.
Chao H, Walsh C
Mt Sinai J Med
. 2004 Nov;
71(5):305-13.
PMID: 15543431
Adeno-associated viral (AAV) vector is attracting significant interest for use in gene therapy for genetic diseases, because of its unique and advantageous characteristics, compared to other currently available viral vectors....
6.
Mansfield S, Chao H, Walsh C
Trends Mol Med
. 2004 Jun;
10(6):263-8.
PMID: 15177190
No abstract available.
7.
Chao H, Mansfield S, Bartel R, Hiriyanna S, Mitchell L, Garcia-Blanco M, et al.
Nat Med
. 2003 Jul;
9(8):1015-9.
PMID: 12847523
Conventional gene therapy of hemophilia A relies on the transfer of factor VIII (FVIII; encoded by the F8 gene) cDNA. We carried out spliceosome-mediated RNA trans-splicing (SMaRT) to repair mutant...
8.
Chao H, Walsh C
Curr Opin Mol Ther
. 2002 Nov;
4(5):499-504.
PMID: 12435052
Hemophilia results from a deficiency of coagulation Factor VIII or IX and manifests clinically as spontaneous bleeding into the large joints and soft tissue. Current treatment relies on the intravenous...
9.
Chao H, Sun L, Bruce A, Xiao X, Walsh C
Mol Ther
. 2002 May;
5(6):716-22.
PMID: 12027555
Adeno-associated virus (AAV) is a useful vector for hemophilia gene therapy, but the limited effective packaging capacity of AAV (5 kb) appears to be incompatible with factor VIII (gene symbol...